Biocon and Mylan have launched their biosimilar insulin glargine, Semglee, in Australia. The general schedule for Semglee lists the biosimilar as “a-flagged,” a designation that allows a product to be substituted at the pharmacy level without consulting with the prescribing physician.
Biocon and Mylan have launched their biosimilar insulin glargine, Semglee, in Australia.
The biosimilar, referencing Lantus, was first approved in Australia in March of 2018 and is covered under Australia’s Pharmaceutical Benefits Scheme (PBS). The PBS general schedule for Semglee lists the biosimilar as “a-flagged,” a designation that allows a product to be substituted for its reference or for other equivalent products at the pharmacy level without consulting with the prescribing physician.
The biosimilar has a price of $181.94 (US $122.23), and a patient charge of $40.30 (US $27.07), for 5 prefilled 3-ml pens. Lantus SoloStar carries the same price and patient charge for 5 of its 3-ml cartridges.
Christiane Hamacher, PhD, the chief executive officer of Biocon Biologics, said in a statement that the company is “extremely excited” to offer the biosimilar to Australian patients with diabetes. “We are confident that availability of Semglee through the Pharmaceutical Benefits Scheme will expand patient access to this therapy in Australia and will reduce the cost burden for PBS. Today, patients in Europe, India and key emerging markets are already benefiting from our biosimilar.”
While Biocon and Mylan have been seeing success for their biosimilar product in the European marketplace, where it was authorized on the basis of data that included those from the phase 3 INSTRIDE 1 study in 558 patients with type 1 diabetes, the partnership has faced numerous challenges in its efforts to gain FDA authorization for the product.
In the United States, where Biocon and Mylan have sought FDA approval for the product as a follow-on insulin (as insulins will not be eligible to be regulated as biosimilars until 2020 when the US market will undergo a regulatory transition for these products), Semglee has faced multiple setbacks. In August, Biocon disclosed that it had been issued with a Complete Response Letter (CRL) for the product. While Biocon indicated that the CRL did not note outstanding scientific issues with the insulin, the FDA had made observations as a result of a pre-approval inspection of Biocon’s insulin manufacturing facility in Malaysia in June 2019.
Biocon and Mylan had previously received a CRL for the follow-on in 2018, after a change of manufacturing site from Bangalore, India to Malaysia.
Eye on Pharma: Bevacizumab Update; Samsung Bioepis, J&J Settlement; Another EU Trastuzumab
December 6th 2023Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
CVS Caremark Switches Up Biosimilar Coverage in 2024
November 27th 2023As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
October 26th 2023Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.